Shanghai Henlius Biotech, Inc. (2696.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap27.97B
Enterprise Value30.8B
P/E Ratio31.54
PEG Ratio6.85
Price/Sales Ratio3.67
Price/Book Ratio6.02
Enterprise/Revenue4.09
Enterprise/EBITDA24.83

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.12
Operating Margin0.12
AD

Management Effectiveness

Return On Assets0.07
Return On Equity0.2

Income Statement

Revenue6.67B
Revenue/Share13.65
Gross Profit4.98B
EBITDA1.16B
Net Income805.64M
Diluted EPS1.47

Balance Sheet

Total Cash956.03M
Total Cash/Share1.75
Total Debt3.95B
Total Debt/Equity0.87
Current Ratio0.78
Book Value Per Share8.33

Price History

52-Week Change-24.03
52-Week High87.1
52-Week Low50.25
Moving Average 50 Days63.27
Moving Average 200 Days66.01

Statistics

Average Volume968,487
Shares Outstanding543.5M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD